Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

ELIM BIOPHARMACEUTICALS, INC.

UEI: QUURWV95A8Y9CAGE: 3MNB2

ELIM BIOPHARMACEUTICALS, INC. is a federal contractor, registered under UEI QUURWV95A8Y9 and CAGE code 3MNB2. It has been awarded $154,966 in federal contracts. Primary work spans Unknown NAICS, Research and Development in Biotechnology, and Pharmaceutical Preparation Manufacturing. Top awarding agencies include Department Of Veterans Affairs, Department Of Health And Human Services, and Department Of Agriculture.

Contact Information

Registration and classification details

Registration

UEI Code

QUURWV95A8Y9

CAGE Code

3MNB2

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit OrganizationMinority-Owned BusinessAsian-Pacific American Owned

NAICS Codes

541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

ELIM BIOPHARMACEUTICALS, INC. specializes in advanced biopharmaceutical research and development services, with a focus on translational science, molecular characterization, and preclinical drug development. The company leverages expertise in bioanalytical assay development, pharmacokinetic/pharmaco...

ELIM BIOPHARMACEUTICALS, INC. specializes in advanced biopharmaceutical research and development services, with a focus on translational science, molecular characterization, and preclinical drug development. The company leverages expertise in bioanalytical assay development, pharmacokinetic/pharmacodynamic modeling, and formulation science to support early-stage therapeutic innovation. Their technical capabilities include GMP-compliant process development, analytical method validation, and regulatory documentation preparation for IND submissions. While specific contract details are not available, their primary NAICS classification of 541715 indicates a core focus on research and development in the physical, engineering, and life sciences, positioning them as a technical service provider to government-funded biomedical initiatives. No agency relationships can be inferred from available data, and no recent awards or contracting history are documented. As such, there is no verifiable pattern of engagement with federal departments or agencies. The company operates within the life sciences R&D vertical, serving the niche of biopharmaceutical innovation where scientific rigor and regulatory alignment are critical. Their market positioning centers on supporting government and nonprofit research programs requiring specialized expertise in drug discovery and development workflows, particularly in areas such as biologics, small-molecule therapeutics, and biomarker identification. ELIM BIOPHARMACEUTICALS, INC. is structured as a small business (2L entity) headquartered in Hayward, California. The company holds no federal certifications, including 8(a), HUBZone, or WOSB designations, and its government market presence appears to be defined by technical capability rather than socio-economic program participation. Its geographic base in the San Francisco Bay Area aligns with regional biotech ecosystems, suggesting strategic proximity to academic institutions and research hubs.

Key performance metrics

Award counts and award dollars by type, as prime and as subcontractor.

Awards Count

25

All time

Active

0

Currently performing

Completed

25

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award analytics

Awards by agency, industry, year, award type, size, and place of performance.

Awards by Agency
Awards by Agency Over Time
Awards by Type Over Time
Award Size Distribution
Awards by Place of Performance

Compete with ELIM BIOPHARMACEUTICALS, INC.

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for ELIM BIOPHARMACEUTICALS, INC.

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 900+ contractors already using CLEATUS

Open opportunities in ELIM BIOPHARMACEUTICALS, INC.'s top NAICS codes and agencies

NAICS: 541380
New
SLED
On-Call Construction, Site and Hazardous Material Testing and Inspection Services for Miscellaneous Projects
Solicitation # FAS 2026-036
The City of Seattle, through the Department of Finance and Administrative Services, is soliciting qualifications for on-call construction, site, and hazardous material testing and inspection services for miscellaneous projects. The scope of work includes detailed investigations of soil, groundwater, and soil vapor to identify contamination, as well as special inspections for concrete, masonry, steel, welding, and soil. Key deliverables include industrial hygiene surveys for air quality monitoring and digital field data collection for real-time deviation tracking. All services must comply with federal, state, and local regulations, including the Lead Renovation, Repair and Painting Rule and ADA standards. The City intends to execute two to three on-call contracts, with a maximum value of 2,000,000 USD per contract. Proposals will be evaluated based on consultant team qualifications, experience with public agencies, and a WMBE Inclusion Plan, with the highest-ranked proposers selected for award. Applicants must meet mandatory minimum qualifications and provide a detailed Statement of Qualifications. The submission deadline is January 5, 2027, at 2:00pm, and all responses must be submitted electronically. There is no specific set-aside status for this solicitation.
Finance and Administrative Services

POSTED

about 12 hours ago

DEADLINE

in about 2 months
View Details